KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Raw Materials (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Raw Materials data on record, last reported at $640000.0 in Q1 2025.

  • For Q1 2025, Raw Materials fell 97.34% year-over-year to $640000.0; the TTM value through Mar 2025 reached $640000.0, down 97.34%, while the annual FY2024 figure was $5.6 million, 207.02% up from the prior year.
  • Raw Materials reached $640000.0 in Q1 2025 per IONS's latest filing, down from $5.6 million in the prior quarter.
  • Across five years, Raw Materials topped out at $24.6 million in Q2 2024 and bottomed at $640000.0 in Q1 2025.
  • Average Raw Materials over 5 years is $17.0 million, with a median of $18.6 million recorded in 2021.
  • Peak YoY movement for Raw Materials: surged 207.02% in 2024, then tumbled 97.34% in 2025.
  • A 5-year view of Raw Materials shows it stood at $18.6 million in 2021, then rose by 5.97% to $19.8 million in 2022, then tumbled by 90.84% to $1.8 million in 2023, then soared by 207.02% to $5.6 million in 2024, then crashed by 88.48% to $640000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $640000.0 in Q1 2025, $5.6 million in Q4 2024, and $21.7 million in Q3 2024.